Question: is sipuleucel-t a passive immunotherapy agent?
Answer: Provenge (sipuleucel- T), the first true cancer vaccine, gained FDA approval for the treatment of hormone-resistance metastatic prostate cancer in 2010 (25). No active specific immunotherapy, or cancer vaccine, is currently approved for the treatment of breast cancer.